Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

References

• Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9:630-9
   PubMed Web of Science ®Google Scholar
• Grant P, Dashora U. High-mix analogue insulins: do they have a therapeutic role? Br J Diabetes Vasc Dis 2009;9:166-70
   Google Scholar
• Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc 2009;109:26-36
   PubMedGoogle Scholar
• Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009;63:1571-77
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycaemia in diabetes. Diabetes 2008;57:3169-76
   PubMed Web of Science ®Google Scholar
• Kushner P. Minimizing the risk of hypoglycaemia in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2010;3:49-53
   PubMedGoogle Scholar
• De Galen BE, Schouwenberg BJ, Tack CJ, et al. Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes. Neth J Med 2006;64:269-79
   PubMed Web of Science ®Google Scholar
• Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-9
   PubMed Web of Science ®Google Scholar
• McSorley PT, Bell PM, Jacobsen LV, et al. Twice daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530-9
   PubMed Web of Science ®Google Scholar
• Qayyum R, Wilson LM, Bolen S, et al. Comparative effectiveness, safety, and indications of insulin analogues in premixed formulations for adults with type 2 diabetes. Comparative Effectiveness Review No. 14. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018) Rockville, MD: Agency for Healthcare Research and Quality. September 2008. Available at: www.effecticehealthcare.ahrq.gov/reports/final.cfm
   Google Scholar
• Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycaemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix 50 Study Group. Clin Ther 1999;21:523-34
   PubMed Web of Science ®Google Scholar
• Swartz S, Zagar AJ, Althouse SK, et al. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006;28:1649-57
   PubMed Web of Science ®Google Scholar
• Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005; 21:989-98
   PubMed Web of Science ®Google Scholar
• Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13
   PubMed Web of Science ®Google Scholar
• Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycaemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther 2009;31:1641-51
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29(6 Pt 1):1284-92
   Web of Science ®Google Scholar
• Shah S, Benroubi M, Borzi V, et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study. Int J Clin Pract 2009;63:574-82
   PubMed Web of Science ®Google Scholar
• Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007;23:3209-14
   PubMed Web of Science ®Google Scholar
• Brito M, Ligthelm RJ, Boemi M, et al. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: a consensus statement. Ind J Endocrinol Metab 2011;15:152-60
   PubMedGoogle Scholar
• Brunton SA. Nocturnal hypoglycaemia: answering the challenge with long-acting insulin analogs. MedGenMed 2007;9:38
   PubMedGoogle Scholar
• Jauch-Chara K, Schultes B. Sleep and the response to hypoglycaemia. Best Pract Res Clin Endocrinol Metab 2010;24:801-15
   PubMed Web of Science ®Google Scholar
• Boehm BO, Vaz JA, Brondstead L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Int Med 2004;15:496-502
   PubMedGoogle Scholar
• Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract 2010;87:64-8
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2009;339:b4909
   Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
   PubMed Web of Science ®Google Scholar
• Velojic-Golubovic M, Mikic D, Pesic M, et al. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest 2009;32:23-7
   PubMed Web of Science ®Google Scholar
• Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883-8
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
   PubMed Web of Science ®Google Scholar
• Yang W, Ji Q, Zhu D, et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycaemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008;31:852-6
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Smirnova O, Christiansen JS, et al. Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab 2009;11:700-8
   PubMed Web of Science ®Google Scholar
• Clements MR, Tits J, Kinsley BT, et al. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008;10:229-37
   PubMed Web of Science ®Google Scholar
• Dashora U, Ashwell SG, Home PD. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab 2009;11:680-7
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Rasmussen M, Kamp N, et al. Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab 2003;5:438-45
   PubMed Web of Science ®Google Scholar
• Heise T, Eckers U, Kanc K, et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008;10:479-85
   PubMed Web of Science ®Google Scholar
• Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006;32(Suppl):9-18S
   Web of Science ®Google Scholar